<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000804.v1.p1" parentStudy="phs000804.v1.p1" createDate="2014-09-23" modDate="2014-09-23">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Kimberly Stegmaier</td><td>Dana-Farber Cancer Institute and Boston Children&#39;s Hospital, Boston, Massachusetts, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Jaume Mora</td><td>Hospital Sant Joan de Deu, Barcelona, Spain</td></tr>
		<tr><td>Principal Investigator</td><td>Gad Getz</td><td>Eli and Edythe L. Broad Institute, Cambridge, Massachusetts, USA; Massachusetts General Hospital, Massachusetts, USA</td></tr>
		<tr><td>Funding Source</td><td>Slim Initiative for Genomic Medicine (SIGMA)</td><td>A joint U.S.-Mexico project founded by the Carlos Slim Health Institute</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Sequencing of Ewing Sarcoma</StudyNameEntrez>
	<StudyNameReportPage>Genomic Sequencing of Ewing Sarcoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Whole Genome Sequencing</StudyType>
		<StudyType>Exome Sequencing</StudyType>
		<StudyType>RNA Sequencing</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Pediatric Ewing sarcoma is a pediatric cancer that primarily arises from the bone. It is characterized by chimeric fusions of the EWS gene and an ETS family transcription factor. In this study, we performed massively parallel sequencing of a larger collection of Ewing sarcoma tumors to define the genomic landscape of this disease. We found that these tumors are among of the most genetically normal cancers currently characterized. There was also a marked absence of recurrent mutations in immediately targetable signaling transduction pathway genes. In this study we answer outstanding questions about ETS transcription factor expression, effects of treatment on mutational burden in Ewing sarcoma tumors, and describe patterns of tumor evolution. We also found that loss-of-function mutations in STAG2 were present in approximately 15% of Ewing sarcoma tumors and loss of STAG2 expression was associated with disease metastasis in this patient cohort.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Ewing sarcoma tumor samples and normal tissue were obtained through IRB approved protocols. A pathologic diagnosis of Ewing sarcoma was required to include a tumor sample in this study.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Brian D. Crompton, Chip Stewart, Amaro Taylor-Weiner, Gabriela Alexe, Kyle C. Kurek, Monica L. Calicchio, Adam Kiezun, Scott L. Carter, 			Sachet A. Shukla, Swapnil S. Mehta, Aaron R. Thorner, Carmen de Torres, Cinzia Lavarino, Mariona Sunol, Aaron McKenna, Andrey Sivachenko, 			Kristian Cibulskis, Michael S. Lawrence, Petar Stojanov, Mara Rosenberg, Lauren Ambrogio, Daniel Auclair, Sara Seepo, Brendan Blumenstiel, 			Matthew DeFelice, Ivan Imaz-Rosshandler, Angela Schwarz-Cruz y Celis, Miguel N. Rivera, Carlos Rodriguez-Galindo, Mark D. Fleming, Todd R. Golub, 			Gad Getz, Jaume Mora, and Kimberly Stegmaier" title="The Genomic Landscape of Pediatric Ewing Sarcoma" journal="Cancer Discovery, 2014"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Sarcoma, Ewing"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Kimberly Stegmaier</AttName>
			<Institution>Dana-Farber Cancer Institute and Boston Children&#39;s Hospital, Boston, Massachusetts, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Jaume Mora</AttName>
			<Institution>Hospital Sant Joan de Deu, Barcelona, Spain</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Gad Getz</AttName>
			<Institution>Eli and Edythe L. Broad Institute, Cambridge, Massachusetts, USA; Massachusetts General Hospital, Massachusetts, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Slim Initiative for Genomic Medicine (SIGMA)</AttName>
			<Institution>A joint U.S.-Mexico project founded by the Carlos Slim Health Institute</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="2" shortName="DS-CA-MDS" longName="Disease-Specific (Cancer, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000804.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000804.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000804.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
